CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Back to LNTH

LNTH2403 Phase 1 dose

Phase 2
Lantheus Holdings, Inc. (LNTH)

Phase 2

Development Phase

1

Upcoming Catalysts

0

Historical Events

0

Regulatory Approvals

Upcoming Catalysts
What are catalysts?
Aug '27
LNTHPhase 2

LNTH2403 Phase 1 dose Phase 2 Est. Readout

LNTH2403 Phase 1 dose
Aug 2027~STALE
CT.gov
00%
Competitive Landscape

0 competitors in Relapsed / Refractory Osteosarcoma

View Full Landscape
Drug Information

Target Indication

Relapsed / Refractory Osteosarcoma

Clinical Trial

NCT07357519

Last updated: 2/10/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Drug Science
Mechanism of action & safety profile
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts

Weekly digest every Monday. Unsubscribe anytime.